Evaluation of the Drug-Like Properties of Kaempferol, Chrysophanol and Emodin and Their Interactions With EGFR Tyrosine Kinase - An in Silico Approach

Natural Product Communications - United States
doi 10.1177/1934578x1701200621
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Comparison of the EGFR Resistance Mutation Profiles Generated by EGFR-targeted Tyrosine Kinase Inhibitors and the Impact of Drug Combinations

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2008English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Kaempferol and Kaempferol Rhamnosides With Depigmenting and Anti-Inflammatory Properties

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2011English

In Silico Design and in Vitro Characterization of Universal Tyrosine Kinase Peptide Substrates

English

Interactions Between PTEN and Receptor Tyrosine Kinase Pathways and Their Implications for Glioma Therapy

Expert Review of Anticancer Therapy
OncologyPharmacology
2009English

Antiproliferative Efficacy of Kaempferol on Cultured Daudi Cells: An in Silico and in Vitro Study

Advances in Biology
2016English

Development, Evaluation, and Application of an in Silico Model for Antimalarial Drug Treatment and Failure

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2011English

Dual Blockade of EGFR Tyrosine Kinase Using Osimertinib and Afatinib Eradicates EGFR‑mutant Ba/F3 Cells

Oncology Reports
MedicineCancer ResearchOncology
2018English

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy